| Literature DB >> 27655321 |
Houyuan Zhao1, Liang Wang1, Dan Wan1, Jianzhao Qi1, Rong Gong1, Zixin Deng1,2, Wenqing Chen3.
Abstract
BACKGROUND: Aurantimycin (ATM), produced by Streptomyces aurantiacus JA 4570, is a potent antimicrobial and antitumor antibiotic. Although the chemical structure of ATM is highly distinctive and features a cyclohexadepsipeptide scaffold attached with a C14 acyl side chain, little is known about its biosynthetic pathway and regulatory mechanism.Entities:
Keywords: Aurantimycin; Biosynthesis; Gene cluster; Pathway-specific activators; Streptomyces
Year: 2016 PMID: 27655321 PMCID: PMC5031334 DOI: 10.1186/s12934-016-0559-7
Source DB: PubMed Journal: Microb Cell Fact ISSN: 1475-2859 Impact factor: 5.328
Fig. 1Chemical structures of ATM, and other related azinothricin-family antibiotics
Fig. 2Organization and confirmation of the ATM biosynthetic gene cluster. a Organization of the ATM gene cluster. The proposed gene functions are listed in Table 1. b Schematic construction of the ΔartG mutant WL01. c Confirmation of the ΔartG mutant WL-01 by PCR. 1 wild type; 2 the ΔartG mutant WL01; M, 1 kb ladder. d HPLC analysis of the extract samples of S. aurantiacus JA 4570 wild type and the mutant WL01
Deduced functions for the orfs in ATM biosynthetic gene cluster
| Protein | Sizea | Accession no. | Proposed function | Homolog. origin | Identity/similarity |
|---|---|---|---|---|---|
| Orf1 | 206 | EFE72573 | Sugar transporter | SSFG_07808, | 82/88 |
| Orf2 | 91 | EME58614 | Phosphopantetheine attachment site domain-containing protein | H074_18583, | 35/65 |
| Orf3 | 181 | AKJ15912 | NADH: riboflavin 5′-phosphate oxidoreductase | ABB07_39600, | 57/67 |
| Orf4 | 393 | EFE72565 | Cytochrome P450 hydroxylase | SSFG_07800 | 76/88 |
| Orf5 | 378 | KTF47283 | Zinc-binding dehydrogenase | APS67_01215, | 82/90 |
| Orf6 | 312 | EFE73053 | 3-Oxoacyl-[acyl-carrier-protein] synthase III | SSGG_00419, | 71/82 |
| Orf7 | 82 | KMO67717 | Phosphopantetheine attachment site domain-containing protein | MCHLDSM_06970, | 38/55 |
| Orf8 | 77 | XP_008613423 | Dihydrolipoamide succinyltransferase | SDRG_09281, | 44/62 |
| Orf9 | 326 | KOX10942 | 2-Oxoisovalerate dehydrogenase | ADK66_07235, | 50/64 |
| Orf10 | 279 | KTF47288 | 3-Methyl-2-oxobutanoate dehydrogenase | APS67_01220, | 86/91 |
| ArtA | 71 | KOG32626 | MbtH-like protein | ADK37_26530, | 87/94 |
| ArtB | 240 | KUN90566 | Putative regulator | AQJ84_39630, | 77/86 |
| ArtC | 530 | KUM93570 | A | AQI88_26200, | 84/90 |
| ArtD | 77 | AKJ15824 | PCP | ABB07_39115, | 84/90 |
| ArtE | 395 | KUM93571 | FAD-dependent oxidoreductase | AQI88_26210, | 81/90 |
| ArtF | 2882 | KUM93572 | C-A-PCP-E-C-A-MT-PCP | AQI88_26215, | 81/88 |
| ArtG | 2574 | KOU40387 | C-A-PCP-E-C-A-PCP | ADK54_22435, | 78/86 |
| ArtH | 1274 | KJY47954 | C-A-PCP-TE | VR46_00735, | 78/87 |
| ArtI | 248 | KUM93575 | TE | AQI88_26230, | 86/90 |
| ArtJ | 312 | KOG32633 | ABC transporter | ADK37_26575, | 86/92 |
| ArtK | 253 | KIF05972 | ABC transporter permease | PL81_10120, | 81/92 |
| ArtL | 73 | KUM93581 | PCP | AQI88_26270, | 86/90 |
| ArtM | 416 | KUM99154 | Cytochrome | AQI95_40375, | 89/93 |
| ArtN | 245 | KUM93583 | TE | AQI88_26280, | 79/87 |
| ArtO | 1034 | KUM93584 | KS-AT-ACP | AQI88_26285, | 80/86 |
| ArtP | 1899 | KUM93585 | KS-AT-DH-KR-ACP | AQI88_26290, | 71/79 |
| ArtQ | 2199 | KUM93586 | KS-AT-DH-ER-KR-ACP | AQI88_26295, | 77/85 |
| ArtR | 1040 | KJY47935 | KS-AT-ACP | VR46_00775, | 81/89 |
| ArtT | 1061 | KUM93588 | C-A-PCP | AQI88_26305, | 72/81 |
| ArtU | 248 | AGK78157 | DUF1838 | SFUL_3223, | 89/93 |
| ArtV | 260 | KUL64059 | Peptidoglycan-binding protein | ADL30_00970, | 77/83 |
| ArtW | 116 | CAJ88026 | Conserved hypothetical protein | SAMR0316, | 78/82 |
| ArtX | 209 | KOT40573 | TetR family Transcriptional regulator | ADK41_12650, | 90/93 |
| Orf11 | 467 | AJE84472 | Integrin-like protein | SLNWT_4096, | 82/88 |
| Orf12 | 261 | AGM04325 | Putative ArsR family transcriptional regulator | AORI_1737, | 45/60 |
| Orf13 | 176 | AKJ08646 | Hypothetical protein ABB07_00890 | ABB07_00890, | 49/62 |
Orf1(STRAU_0320)…………Orf12(STRAU_0357)
aNumbers are in amino acids
Fig. 3Genetic characterization of artB and artX as positive regulatory genes for ATM biosynthesis. a HPLC analysis of ATM-A production by related recombinants of S. aurantiacus. WT, wild type S. aurantiacus JA 4570; ΔartB, the ΔartB mutant WL02 of S. aurantiacus; ΔartB::pIB139, ΔartB mutant WL02 containing pIB139 as negative control; ΔartB::artB, ΔartB mutant WL02 containing pIB139/artB for complementation; ΔartX, the ΔartX mutant WL03 of S. aurantiacus; ΔartX::pIB139, ΔartX mutant WL03 containing pIB139 as negative control; ΔartX::arX, ΔartX mutant WL03 containing pIB139/artX for complementation; b Comparative analysis of ATM-A production produced by related recomniants of S. aurantiacus. All measurements were conducted in triplicate
Fig. 4Individual overexpression of artB, artX as well as artB & artX in S. aurantiacus remarkably enhances ATM-A production. a HPLC analysis of the ATM-A production by relevant S. aurantiacus recombinants. b Comparative analysis of the ATM-A production by target strains. WT, S. aurantiacus wild type; WT::pIB139, S. aurantiacus containing pIB139 as negative control; WT::artX, S. aurantiacus containing pIB139/artX; WT::artB, S. aurantiacus containing pIB139/artB; WT::artB & artX, S. aurantiacus containing pIB139/artB & artX. All measurements were conducted in triplicate
Fig. 5Substrate specificities of four adenylation domains ArtC, ArtF-A2, ArtG-A1, and ArtH-A in vitro. NC, no amino acid substrate. All amino acid substrates (4 mM) are L type, unless otherwise indicated. The background has been subtracted. Error bars represent standard deviations from three independently performed experiments
Fig. 6Proposed biosynthetic pathway for ATM. a The proposed model for ATM scaffold assembly line driven by the hybrid PKS/NRPS system. KS ketosynthase, AT acyltransferase, ACP acyl carrier protein, DH dehydratase, KR ketoreductase, ER enoylreductase, A adenylation domain, PCP peptidyl carrier protein, C condensation domain, MT methyltransferase domain, E epimerase domain, TE thioesterase domain. b The proposed pathway for the biosynthesis of 2-(2-methylpropyl)malonyl-ACP; c The proposed pathway for the biosynthesis of the nonproteinogenic amino acids building blocks